NOTE 4 – SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:
| |
|
Six months ended
June 30
|
|
|
Three months ended
June 30
|
|
| |
|
2025
|
|
|
2026 |
|
|
2025
|
|
|
2026 |
|
| Royalties revenue |
|
$ |
683 |
|
|
$ |
- |
|
|
$ |
530 |
|
|
$ |
- |
|
| Sale of IP and license revenue |
|
|
17,577 |
|
|
|
568 |
|
|
|
16,717 |
|
|
|
460 |
|
| Support services |
|
|
32 |
|
|
|
131 |
|
|
|
14 |
|
|
|
131 |
|
| Total revenue |
|
$ |
18,292 |
|
|
$ |
699 |
|
|
$ |
17,261 |
|
|
$ |
591 |
|
Research and development expenses:
| |
|
Six months ended
June 30
|
|
|
Three months ended
June 30
|
|
| |
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
| Payroll and related expenses |
|
$ |
1,687 |
|
|
$ |
2,083 |
|
|
$ |
763 |
|
|
$ |
1,026 |
|
| Clinical and preclinical trials expenses |
|
|
3,660 |
|
|
|
1,992 |
|
|
|
1,850 |
|
|
|
1,590 |
|
| Professional consulting and subcontracted work |
|
|
4,722 |
|
|
|
1,819 |
|
|
|
1,656 |
|
|
|
797 |
|
| Supplier-led manufacturing development |
|
|
2,749 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Other |
|
|
671 |
|
|
|
611 |
|
|
|
377 |
|
|
|
306 |
|
| Total Research and development expenses |
|
$ |
13,489 |
|
|
$ |
6,505 |
|
|
$ |
4,646 |
|
|
$ |
3,719 |
|
|